Ying-Chuan Lin
Overview
Explore the profile of Ying-Chuan Lin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
448
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lin Y, Happer M, Elder J
J Virol
. 2013 May;
87(15):8524-34.
PMID: 23720716
An infectious chimeric feline immunodeficiency virus (FIV)/HIV strain carrying six HIV-like protease (PR) mutations (I37V/N55M/V59I/I98S/Q99V/P100N) was subjected to selection in culture against the PR inhibitor lopinavir (LPV), darunavir (DRV), or...
2.
Tiefenbrunn T, Forli S, Baksh M, Chang M, Happer M, Lin Y, et al.
ACS Chem Biol
. 2013 Apr;
8(6):1223-31.
PMID: 23540839
The fragment indole-6-carboxylic acid (1F1), previously identified as a flap site binder in a fragment-based screen against HIV protease (PR), has been cocrystallized with pepstatin-inhibited PR and with apo-PR. Another...
3.
Lin Y, Torbett B, Elder J
J Virol
. 2010 Apr;
84(13):6799-809.
PMID: 20410281
Feline immunodeficiency virus (FIV) and human immunodeficiency virus type 1 (HIV-1) proteases (PRs) share only 23% amino acid identity and exhibit distinct specificities yet have very similar 3-dimensional structures. Chimeric...
4.
Elder J, Lin Y, Fink E, Grant C
Curr HIV Res
. 2010 Mar;
8(1):73-80.
PMID: 20210782
FIV is a significant pathogen in the cat and is, in addition, the smallest available natural model for the study of lentivirus infections. Although divergent at the amino acid level,...
5.
Giffin M, Heaslet H, Brik A, Lin Y, Cauvi G, Wong C, et al.
J Med Chem
. 2008 Oct;
51(20):6263-70.
PMID: 18823110
Treatment with HIV-1 protease inhibitors, a component of highly active antiretroviral therapy (HAART), often results in viral resistance. Structural and biochemical characterization of a 6X protease mutant arising from in...
6.
Elder J, Sundstrom M, de Rozieres S, de Parseval A, Grant C, Lin Y
Vet Immunol Immunopathol
. 2008 Feb;
123(1-2):3-13.
PMID: 18289701
Feline immunodeficiency virus (FIV) is an important viral pathogen worldwide in the domestic cat, which is the smallest animal model for the study of natural lentivirus infection. Thus, understanding the...
7.
Heaslet H, Lin Y, Tam K, Torbett B, Elder J, Stout C
Retrovirology
. 2007 Jan;
4:1.
PMID: 17212810
We have obtained the 1.7 A crystal structure of FIV protease (PR) in which 12 critical residues around the active site have been substituted with the structurally equivalent residues of...
8.
Whiting M, Tripp J, Lin Y, Lindstrom W, Olson A, Elder J, et al.
J Med Chem
. 2006 Dec;
49(26):7697-710.
PMID: 17181152
Building from the results of a computational screen of a range of triazole-containing compounds for binding efficiency to human immunodeficiency virus type 1 protease (HIV-1-Pr), a novel series of potent...
9.
Lin Y, Brik A, de Parseval A, Tam K, Torbett B, Wong C, et al.
J Virol
. 2006 Jul;
80(16):7832-43.
PMID: 16873240
We have used feline immunodeficiency virus (FIV) protease (PR) as a mutational system to study the molecular basis of substrate-inhibitor specificity for lentivirus PRs, with a focus on human immunodeficiency...
10.
Whiting M, Muldoon J, Lin Y, Silverman S, Lindstrom W, Olson A, et al.
Angew Chem Int Ed Engl
. 2006 Jan;
45(9):1435-9.
PMID: 16425339
No abstract available.